PDL BioPharma Stock Price and Value Analysis

Should you buy PDL BioPharma stock? (NasdaqGS:PDLI). Let's see how it does in our automated value investing analysis system.

PDLI Free Cash Flow Trend

Free Cash Flow trendline for PDLI
Free Cash Flow trendline for PDL BioPharma

Hmm, we can't give any reliable projection for PDL BioPharma's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This company has wild ups and downs.
  • This stock looks overpriced.
  • This company is not making money.
  • This company pays no dividend.

Inside the PDLI Numbers

PDLI Price
(PDL BioPharma stock price per share)
PE Ratio versus Sector 83% lower than other Healthcare stocks
PE Ratio versus Industry 94% lower than other Biotechnology stocks
Cash Yield 97.45%
Free Cash Flow Jitter 40%

Is PDL BioPharma Stock on Sale?

Based on our analysis, we believe that you should not buy PDL BioPharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy PDLI Stock?

Does PDL BioPharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.